TCL Archive IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC March 28, 2014
TCL Archive NCI Committed To 50 Percent Mortality Reduction By 2000; DCPC Board Hears How That Will Be Done January 20, 1984
TCL Archive Letter to the Editors: Researchers Must Keep Up NIH Advocacy Particularly Now October 11, 1996
